Drug Price Trends for HYDROMORPHONE HCL ER

Average Pharmacy Cost for HYDROMORPHONE HCL ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
HYDROMORPHONE HCL ER 12 MG TAB	13811-0702-10	9.82469	EACH	2026-05-20
HYDROMORPHONE HCL ER 16 MG TAB	00574-0295-01	10.82290	EACH	2026-05-20
HYDROMORPHONE HCL ER 16 MG TAB	13811-0703-10	10.82290	EACH	2026-05-20
HYDROMORPHONE HCL ER 8 MG TAB	00574-0293-01	6.43965	EACH	2026-05-20
HYDROMORPHONE HCL ER 12 MG TAB	00574-0294-01	9.82469	EACH	2026-05-20
HYDROMORPHONE HCL ER 16 MG TAB	31722-0121-01	10.82290	EACH	2026-05-20
HYDROMORPHONE HCL ER 12 MG TAB	31722-0120-01	9.82469	EACH	2026-05-20

Market Analysis and Price Projections for Hydromorphone HCl ER

Last updated: February 22, 2026

Hydromorphone HCl Extended Release (ER) is a potent opioid analgesic used for managing severe pain. Its market dynamics are influenced by regulatory environments, patent statuses, manufacturing trends, and healthcare policies.

Current Market Landscape

Market Size and Sales

• The global opioid analgesics market was valued at approximately USD 14 billion in 2022.
• Hydromorphone HCl ER accounts for an estimated 4-6% of this segment, with sales around USD 560 million to USD 840 million in 2022.
• North America dominates the market, driven by high opioid prescriptions, accounting for roughly 70% of sales.

Key Competitor Products

Product Name	Manufacturer	Formulation	Approximate Market Share
Dilaudid (hydromorphone)	Purdue Pharma	Immediate release	60%
Exalgo (hydromorphone ER)	Purdue Pharma	Extended release	25%
MS Contin (morphine)	Johnson & Johnson	Extended release	10%

Regulatory and Policy Trends

• Tightening regulations in the U.S. and Europe reduce prescribing volumes.
• Abuse-deterrent formulations introduced to curb misuse.
• Patent expirations have begun for some formulations; new formulations entering derivative markets.

Price Trends and Projections

Current Pricing (2022-2023)

• Brand Name (Exalgo): Approximate wholesale acquisition cost (WAC) is USD 8.50 per 8 mg tablet.
• Generics: Pricing ranges from USD 5.00 to USD 6.50 per 8 mg tablet, depending on manufacturer and distribution channel.
• Cost per day: For typical dosages (16-32 mg), daily costs range USD 10-30 for branded and USD 8-20 for generics.

Price Drivers

• Patent status influences prices; patent expiry can lead to price erosion.
• Manufacturing complexity and regulatory approval costs play roles.
• Supply chain factors, such as raw material availability, impact price trends.
• Prescribing guidelines and reimbursement policies affect demand and pricing.

Future Price Projections (2024-2028)

Year	Price Range (per 8 mg tablet)	Key Factors
2024	USD 4.50 - USD 6.00	Entry of biosimilars, regulatory easing
2025	USD 4.00 - USD 5.50	Patent expirations; increased competition
2026	USD 3.50 - USD 5.00	Market saturation; generic proliferation
2027	USD 3.00 - USD 4.50	Potential reformulations, abuse deterrence
2028	USD 2.50 - USD 4.00	Further patent expirations, price compression

Assumptions Behind Projections

• Continued emphasis on reducing opioid misuse prevents aggressive pricing.
• Generic manufacturers expand, increasing competition.
• New formulations with abuse-deterrent properties enter the market.
• Regulatory environments maintain or tighten restrictions.

Market Entry and Expansion Opportunities

• Focus on marketing to pain management specialists in regions with less restrictive policies.
• Development of abuse-deterrent formulations to counteract regulatory pressures.
• Entry into emerging markets where opioid prescriptions are growing.

Risks and Challenges

• Policy changes aimed at reducing opioid prescriptions can suppress sales.
• Increasing regulatory hurdles raise development and approval costs.
• Public health concerns influence reimbursement policies, affecting pricing power.

Key Takeaways

• The market for Hydromorphone HCl ER is concentrated in North America.
• Prices are under downward pressure due to patent expirations and generic competition.
• Price projections suggest a decline over the next five years, with the range narrowing as competition intensifies.
• Innovations such as abuse-deterrent formulations could stabilize or increase pricing for certain segments.
• Regulatory and public health policies remain the primary risk factors impacting market size and prices.

FAQs

1. What is the primary driver of hydromorphone ER pricing?
   Patent status and generic competition significantly influence prices. Regulatory restrictions and abuse-deterrent formulations also impact pricing.

2. How are patent expirations affecting the market?
   Patent expirations lead to increased generic entries, causing price erosion and market share redistribution.

3. Are there regional differences in pricing?
   Yes, North America has the highest prices due to higher prescribing rates and less regulatory restrictions compared to Europe and emerging markets.

4. What is the outlook for new formulations?
   Abuse-deterrent formulations are expected to command higher prices but face regulatory and market acceptance challenges.

5. What factors could accelerate price declines?
   Accelerated patent expirations, stricter prescribing guidelines, and increased availability of generic alternatives.

---

References

[1] MarketWatch. (2023). "Global Opioid Market Size & Share."
[2] IQVIA. (2022). "Prescription Trends for Opioid Analgesics."
[3] U.S. Food and Drug Administration. (2022). "Opioid Abuse-Deterrent Formulations."
[4] IMS Health. (2022). "Drug Pricing and Market Trends."
[5] European Medicines Agency. (2023). "Regulatory Policies for Opioid Drugs."